Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

Absci posts widening losses as it ramps R&D ahead of key ABS-201 trial data.

What the company is saying

Absci Corporation reports a net loss of $33.3 million for Q3 2026, up from $28.7 million in Q3 2025, as it accelerates investment in its internal pipeline, particularly ABS-201 for pattern hair loss and endometriosis. The company highlights upcoming clinical milestones: 13-week interim proof-of-concept data for ABS-201 in December 2026 and full 26-week data in early 2027, with a Phase 2 trial for endometriosis planned for mid-2027. Management frames ABS-201 as a potentially transformative therapy, citing a favorable safety profile and an estimated half-life of at least 65 days, though no efficacy data are yet disclosed. The appointment of Gerry Muhle, a former Galderma executive with over 25 years of experience, as Chief Commercial Officer is positioned as a step toward commercial readiness. The company emphasizes its $173.7 million cash and marketable securities balance as sufficient to fund operations into the second half of 2028. Absci also references recent scientific presentations supporting its mechanistic rationale for ABS-201.

What the data suggests

Revenue for the quarter was $0.3 million, down from $0.4 million a year earlier, with partner program revenue declining to $304,000 from $378,000. Research and development expenses rose to $23.6 million from $19.2 million, primarily due to increased spending on ABS-201's clinical and nonclinical development. Selling, general, and administrative expenses increased to $9.0 million from $8.4 million, mainly due to higher stock-based compensation. Total operating expenses reached $35.3 million, up from $30.5 million, driving an operating loss of $35.0 million versus $30.2 million last year. Net loss per share was $(0.19), slightly improved from $(0.20) due to a higher share count. Cash, cash equivalents, and marketable securities fell to $173.7 million from $201.1 million at the end of June 2026, reflecting ongoing cash burn. The company projects its current cash will fund operations into the second half of 2028. No clinical efficacy data for ABS-201 are disclosed; all clinical milestones remain pending.

Analysis

The announcement is largely factual, with detailed financial disclosures showing increased R&D spending, widening losses, and a declining revenue trend. The company's narrative emphasizes pipeline progress and upcoming clinical milestones, but most key value drivers (ABS-201 efficacy, Phase 2 trial initiation, and proof-of-concept data) remain forward-looking, with the next data readout expected in December 2026 and a Phase 2 trial not starting until mid-2027. While the company highlights 'favorable safety data' and a long half-life for ABS-201, no granular clinical results are provided. The capital intensity is high, with significant ongoing R&D spend and no near-term revenue prospects, but the company asserts a cash runway into 2028. The tone is measured, but the gap between narrative and realised value is moderate: operational progress is real, but commercial and clinical validation are still pending.

Risk flags

• ●Absci's financial trajectory shows rising losses and declining revenue, with a net loss of $33.3 million in Q3 2026 and cash burn reducing reserves from $201.1 million to $173.7 million in a single quarter. Sustained high R&D spending without near-term revenue increases pressure on future funding needs if clinical milestones are delayed or unsuccessful.
• ●The company's lead asset, ABS-201, is still in early clinical development. No efficacy data have been disclosed, and all value hinges on upcoming proof-of-concept results. Failure to demonstrate efficacy or safety in the imminent data readouts would materially undermine the investment case.
• ●The planned Phase 2 STORYLINE trial for endometriosis will not begin until mid-2027, pushing any potential commercial impact further into the future. Delays in trial initiation, enrollment, or regulatory clearance could extend the timeline and increase capital requirements.
• ●While the appointment of a seasoned Chief Commercial Officer signals intent to commercialize, the lack of near-term commercial products means this hire's impact will depend entirely on future clinical success. There is no guarantee that experience alone will translate into market adoption or revenue.

Bottom line

Absci is burning significant cash to advance ABS-201, with losses widening as R&D ramps up and revenue remains minimal. The company is approaching a key inflection point, with interim proof-of-concept data for ABS-201 due in December 2026 and full data in early 2027. Until those results are disclosed, the investment case rests on unproven clinical potential and management's ability to execute. The cash runway into the second half of 2028 provides some buffer, but continued losses and long-dated timelines for endometriosis development increase execution risk. Investors should focus on the upcoming ABS-201 data readout, as it will determine whether the current spending translates into future value. The most important takeaway is that Absci remains a high-risk, high-reward clinical-stage story, with all near-term value contingent on imminent trial results.

Announcement summary

(NASDAQ:ABSI) Absci Corporation reported financial and operating results for the quarter ended September 30, 2026. The company is advancing ABS-201, a prolactin receptor inhibitor, for pattern hair loss (PHL) and endometriosis, with the HEADLINE Phase 1/2a trial ongoing for PHL and the planned STORYLINE Phase 2 trial for endometriosis expected to initiate in mid-2027. Absci anticipates reporting 13-week interim proof-of-concept data for ABS-201 in December 2026 and full 26-week data in early 2027. The company appointed Gerry Muhle, former Galderma executive, as Chief Commercial Officer, bringing over 25 years of experience in pharma, aesthetics, and consumer brands. For the three months ended September 30, 2026, revenue was $0.3 million, compared to $0.4 million for the same period in 2025. Research and development expenses were $23.6 million, up from $19.2 million in the prior year period, primarily due to advancement of internal programs and external nonclinical and clinical development of ABS-201. Selling, general, and administrative expenses were $9.0 million, compared to $8.4 million, mainly due to stock-based compensation. Net loss for the quarter was $33.3 million, compared to $28.7 million in the prior year period. Cash, cash equivalents, and marketable securities as of September 30, 2026, were $173.7 million, down from $201.1 million as of June 30, 2026. The company believes its cash, cash equivalents, and marketable securities will be sufficient to fund operating plans into the second half of 2028. For the nine months ended September 30, 2026, revenue was $0.8 million, research and development expenses were $65.5 million, selling, general, and administrative expenses were $27.3 million, and net loss was $96.1 million. As of September 30, 2026, total assets were $239.6 million and total liabilities were $20.9 million. The company had 171,799,223 weighted-average common shares outstanding for the quarter. Recent scientific presentations included data on ABS-201's mechanism and efficacy in hair growth and endometriosis models at major conferences. The company continues to advance its internal pipeline and partnered programs, including ABS-202, an anti-PRLR antibody in preclinical development for an undisclosed I&I indication. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland.

Disagree with this article?